United Therapeutics Corp [UTHR] stock is trading at $237.93, up 0.42%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The UTHR shares have gain 2.30% over the last week, with a monthly amount glided 0.51%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
United Therapeutics Corp [NASDAQ: UTHR] stock has seen the most recent analyst activity on February 12, 2024, when Goldman upgraded its rating to a Neutral and also boosted its price target to $215 from $213. Previously, Leerink Partners started tracking the stock with Outperform rating on February 05, 2024, and set its price target to $330. On December 08, 2023, Wells Fargo initiated with a Overweight rating and assigned a price target of $309 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $320 on December 06, 2022. Goldman initiated its recommendation with a Sell and recommended $230 as its price target on December 05, 2022. Morgan Stanley started tracking with a Overweight rating for this stock on October 11, 2022, and assigned it a price target of $288. In a note dated September 20, 2022, BofA Securities reiterated an Underperform rating on this stock.
United Therapeutics Corp [UTHR] stock has fluctuated between $204.44 and $261.54 over the past year. Currently, Wall Street analysts expect the stock to reach $268.75 within the next 12 months. United Therapeutics Corp [NASDAQ: UTHR] shares were valued at $237.93 at the most recent close of the market. An investor can expect a potential return of 12.95% based on the average UTHR price forecast.
Analyzing the UTHR fundamentals
United Therapeutics Corp [NASDAQ:UTHR] reported sales of 2.33B for the trailing twelve months, which represents a growth of 25.07%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at 0.51%, Pretax Profit Margin comes in at 0.55%, and Net Profit Margin reading is 0.42%. To continue investigating profitability, this company’s Return on Assets is posted at 0.14, Equity is 0.18 and Total Capital is 0.19. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 235.75 points at the first support level, and at 233.56 for the second support level. However, for the 1st resistance point, the stock is sitting at 239.23, and for the 2nd resistance point, it is at 240.52.
Ratios To Look Out For
For context, United Therapeutics Corp’s Current Ratio is 4.41. Further, the Quick Ratio stands at 4.28, while the Cash Ratio is 1.5. Considering the valuation of this stock, the price to sales ratio is 4.81, the price to book ratio is 1.87 and price to earnings (TTM) ratio is 11.99.
Transactions by insiders
Recent insider trading involved ROTHBLATT MARTINE A, CHAIRPERSON & CEO, that happened on Apr 18 ’24 when 3600.0 shares were sold. CHAIRPERSON & CEO, ROTHBLATT MARTINE A completed a deal on Apr 17 ’24 to sell 3600.0 shares. Meanwhile, CHAIRPERSON & CEO ROTHBLATT MARTINE A sold 3600.0 shares on Apr 16 ’24.
